Are Robust Financials Driving The Recent Rally In TG Therapeutics, …

Sep 19, 2024 · Are Robust Financials Driving The Recent Rally In TG Therapeutics, Inc.'s (NASDAQ:TGTX) Stock? [email protected] (Simply Wall St) Thu, Sep 19, …

78%
OFF

Evaluating TG Therapeutics: Insights From 4 Financial Analysts

2 weeks from now

Sep 18, 2024 · Return on Assets (ROA): TG Therapeutics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.78%, the …

nasdaq.com

9%
OFF

Why TGTX Stock Is Rallying Today - Yahoo Finance

2 weeks from now

19 hours ago · The shares of drug maker TG Therapeutics (TGTX) are climbing 9% today after the firm preannounced higher-than-expected 2024 revenue from its multiple sclerosis drug, …

yahoo.com

26%
OFF

TG Therapeutics Stock Jumps After Q4 Beat (NASDAQ:TGTX)

2 weeks from now

Feb 28, 2024 · TG Therapeutics (NASDAQ:TGTX) shares rose ~26% in the morning hours on Wednesday after the biotech exceeded expectations with its Q4 2023 financials, recording its …

seekingalpha.com

15%
OFF

Earnings Call: TG Therapeutics Reports Robust Growth For BRIUMVI

2 weeks from now

Nov 4, 2024 · TG Therapeutics aims for BRIUMVI to become a blockbuster brand and plans to expand patient outreach efforts and investments in 2025. The company holds a 15% market …

investing.com

15%
OFF

TG Therapeutics Stock Soars Nearly 15% After Topping Deloitte's …

2 weeks from now

Nov 21, 2024 · Warning! GuruFocus has detected 8 Warning Signs with TGTX. Fueled by robust market uptake, TG Therapeutics reported $83.3 million in Q3 2024 U.S. BRIUMVI revenuea …

yahoo.com

$55
OFF

TG Therapeutics Price Target Raised To $55 From $49 At H.C

2 weeks from now

Nov 4, 2024 · H.C. Wainwright raised the firm’s price target on TG Therapeutics (TGTX) to $55 from $49 and keeps a Buy rating on the shares. TG Therapeutics reported Q3 results, …

nasdaq.com

FAQs about Are Robust Financials Driving The Recent Rally In TG Therapeutics, … Coupon?

Why did TG Therapeutics stock rise Wednesday?

TG Therapeutics stock rose Wednesday after the company unveiled promising five-year test results for its multiple sclerosis drug, Briumvi. Stocks closed lower and at session lows in the stock market today after the Federal Reserve decided to cut short-term interest rates by half a point. ...

How did TG Therapeutics perform in the third quarter 2024?

In their third quarter 2024 financial report, TG Therapeutics reported significant growth in BRIUMVI sales, achieving $83.3 million in U.S. net revenue, a 15% increase from the previous quarter, and raised their full-year revenue guidance to $300-$305 million. ...

Why did TG Therapeutics (tgtx) shares rise 26%?

TG Therapeutics ( NASDAQ: TGTX) shares rose ~26% in the morning hours on Wednesday after the biotech exceeded expectations with its Q4 2023 financials, recording its second consecutive quarterly beat for the year. ...

Is TG Therapeutics stock the IBD stock of the day?

TG Therapeutics stock broke out Monday less than two weeks after the biotech company reported a surprise profit for the June quarter. TG Therapeutics stock is the IBD Stock Of The Day as shares approach two potential entries on newfound profitability and booming sales. In January 2024, Precision entered a licensing agreement with TG Therapeutics. ...

What is TG Therapeutics doing in 2025?

TG Therapeutics' progress, particularly with BRIUMVI and its anticipated milestones for 2025, demonstrates the company's commitment to growth and innovation in the treatment of autoimmune diseases and B-cell malignancies. ...

What is TG Therapeutics' Roe?

In this article, we decided to focus on TG Therapeutics' ROE. ROE or return on equity is a useful tool to assess how effectively a company can generate returns on the investment it received from its shareholders. Put another way, it reveals the company's success at turning shareholder investments into profits. ...